Global Molecular Imaging Market Size, Share, Opportunities, And Trends By Device Type (Positron Emission Tomography Scanner, Single Photon Emission Computed Tomography Scanner, Gamma Camera, Nuclear Magnetic Resonance Spectrometer, Others), By Application (Cardiovascular, Neurology, Respiratory, Oncology, Other), By End-User (Hospitals, Ambulatory Surgical Centers, Diagnostic Imaging Centers), And By Geography - Forecasts From 2024 To 2029

The molecular imaging market is poised to expand at a high CAGR over the forecast period.

The molecular imaging market has experienced considerable development and technical breakthroughs in recent years, transforming the area of medical diagnostics. This market comprises a varied variety of modalities that use sophisticated imaging techniques at the molecular and cellular levels, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and computed tomography (CT). The rising frequency of chronic illnesses, along with a growing emphasis on customized therapy, has spurred demand for precise and non-invasive diagnostic technologies, moving the molecular imaging industry ahead. Advances in radiopharmaceuticals, greater imaging resolution, and the incorporation of artificial intelligence are driving forces leading to the continuous expansion of this dynamic and transformational industry, eventually improving diagnostic capabilities and patient outcomes.

Introduction:

The Molecular Imaging Market is a subset of medical imaging that focuses on the viewing and characterization of biological processes at the molecular and cellular levels. Molecular imaging allows for the non-invasive assessment of physiological and biochemical activity within the body by utilizing modern imaging technologies such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Based on molecular markers, this diagnostic technique enables doctors to acquire insights into disease processes, measure therapy response, and tailor patient care. The Molecular imaging Market is critical to the advancement of precision medicine, providing a better knowledge of illnesses and assisting in the creation of focused therapy solutions. Several factors are driving the growth of the Molecular imaging Market. For instance, the growing frequency of complicated illnesses such as cancer and neurological disorders increases the necessity for better diagnostic tools capable of delivering precise molecular insights. The combination of molecular imaging with additional diagnostic modalities, such as computed tomography (CT) and ultrasound, improves diagnostic accuracy and illness evaluation. Furthermore, continuing research and development activities are centred on the identification of novel imaging agents and technologies, which will broaden the scope of molecular imaging applications. As the healthcare sector emphasizes customized therapy and early illness detection, the Molecular Imaging Market is poised for long-term expansion, fueled by technical advances and greater knowledge of molecular processes in health and disease.

Drivers:

• Growing chronic disease:

The increased prevalence of chronic illnesses, particularly cancer and cardiovascular disorders, is a main driver of the molecular imaging market's expansion. According to World Health Organization figures published in February 2020, cancer is the most prevalent cause of death globally, accounting for over 10 million deaths in 2020.  Given the worldwide burden of chronic diseases, there is a greater need for better diagnostic instruments that can provide precise and early diagnosis. PET and SPECT, for example, are crucial in improving diagnosis accuracy, monitoring disease progression, and customizing customized treatment regimens. The adoption of these technologies is increasing as they become more important in the management of complicated medical problems, adding considerably to the growth of the molecular imaging market

• Growing government funding and initiatives:

As policymakers acknowledge the importance of improved diagnostic technologies in healthcare, government efforts and financing play an important role in boosting the molecular imaging industry. Government funding encourages research and development, which drives innovation and the use of molecular imaging technologies. These programs attempt to improve hospital infrastructure, diagnostic capabilities, and public health concerns, all while harmonizing with larger healthcare aims. Governments contribute to the accessibility and affordability of molecular imaging technologies by stimulating developments, thereby benefiting both healthcare professionals and patients and fostering the market's long-term growth. For instance, the "EARLYBRAIN" project was chosen for financing by the Horizon Europe program in December 2023. This €21 million project intends to create a combined PET-MRI imaging technique for the early identification of Alzheimer's disease, perhaps allowing for earlier intervention and improved patient outcomes.

• Integration with the AI:

Artificial intelligence (AI) integration in the molecular imaging business has transformed diagnostic capabilities. Artificial intelligence systems evaluate complicated imaging data, allowing for precise and speedy interpretation of molecular imaging results. Machine learning algorithms help in the detection of subtle patterns, the prediction of illness development, and the optimization of treatment regimens. For instance, in February 2023, GE HealthCare announced the signing of an agreement to purchase Caption Health, Inc., a healthcare firm that develops clinical apps to aid in early illness diagnosis and uses artificial intelligence to assist in ultrasound scans. Leveraging Caption Health, Inc.'s AI technologies, ultrasound examinations may be made easier and faster, allowing a broader spectrum of healthcare practitioners to do basic echocardiography tests. Hence, the expanding role of AI in molecular imaging not only increases efficiency but also creates opportunities for the development of novel imaging techniques, opening the way for more tailored and effective patient treatment.

Products offered by key companies:

• Omni Legend, GE Healthcare: The Omni Legend from GE Healthcare is a cutting-edge solution for molecular imaging. It effortlessly merges PET and CT functions, providing exceptional precision in diagnostics by unleashing the power of sophisticated technology. The Omni Legend guarantees efficient productivity and precise results with an easy UI and rapid imaging capabilities. Omni Legend's adaptability, along with superb picture quality, distinguishes it as a leading solution, changing medical imaging and contributing to improved patient care in a variety of clinical settings.
• Vereos Digital PET/CT, Koninklijke Philips N.V: Vereos is the world's first and only completely digital, clinically verified PET/CT system, backed by rigorous clinical data. Vereos illustrates an established comprehensive solution to disclose more, earlier, to help you enhance patient care and control costs, using unique Digital Photon Counting technology for amazing advancements throughout the imaging chain.

The prominent growth is projected in the hospital sector under the End-User segment

The hospital sector is anticipated to emerge as the dominant force in the molecular imaging market in the future years, owing to rising demand for cutting-edge methods and the widespread availability of sophisticated services. Developed countries, in particular, have seen a tremendous increase in the use of these cutting-edge hospital systems. The growing demand for accurate and timely diagnosis, along with the changing landscape of medical technology, places hospitals in a unique position to capitalize on the benefits of molecular imaging. The potential of molecular imaging to give deep insights into physiological processes at the molecular level improves diagnostic precision and assists in the development of individualized treatment plans. Furthermore, continual improvements in imaging technologies in hospital settings contribute to the segment's strong expected growth during the projection period. This pattern reflects a paradigm shift toward more advanced and efficient diagnostic techniques, confirming the hospital segment's essential role in driving the expansion of the molecular imaging industry.

The North American region is expected to hold a significant share of the molecular imaging market:

The North American area is projected to become the leading market in the molecular imaging sector in the next years, owing to the dominance of established companies that are constantly embarking on strategic efforts to produce novel products. The proactive actions taken by these industry leaders, exhibiting a dedication to keeping at the forefront of technical innovations, maintain the region's market leadership. Furthermore, the constant increase in FDA clearances for molecular imaging devices in North America broadens the market's growth potential substantially. This regulatory backing not only boosts the legitimacy of innovative solutions but also instils trust in consumers and healthcare professionals, promoting wider adoption. The convergence of aggressive initiatives by established market participants and an increasingly favourable regulatory environment puts North America as a key centre for breakthroughs and market progress in the dynamic area of molecular imaging.

Key developments:

• Qure.ai, a health tech startup, raised US$ 40 million in a fundraising round headed by Novo Holdings and HealthQuad in March 2022. MassMutual Ventures, an existing investor, also participated in the round. The funds will be utilized to expand its presence in the United States and Europe.

Segmentation:

• By Devic Type
  • Positron Emission Tomography Scanner
  • Single Photon Emission Computed Tomography Scanner
  • Gamma Camera
  • Nuclear Magnetic Resonance Spectrometer
  • Others
• By Application
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology
  • Other
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Indonesia
    • Thailand
    • Others